-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MOzS1l2Bg9bMeRGbujCSNjaVzrynnNM2OmWXZlP+Tll7BiaAz3nt/30su8lIy0Py ZGmFD2ZToSPMkMj8KpgWGA== /in/edgar/work/20000706/0000891092-00-000589/0000891092-00-000589.txt : 20000920 0000891092-00-000589.hdr.sgml : 20000920 ACCESSION NUMBER: 0000891092-00-000589 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000706 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: [5122 ] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-48691 FILM NUMBER: 668333 BUSINESS ADDRESS: STREET 1: 1617 JFK BLVD #660 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 2159880080 MAIL ADDRESS: STREET 1: 1617 JFK BLVD STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BELSON JEROME CENTRAL INDEX KEY: 0000900685 STANDARD INDUSTRIAL CLASSIFICATION: [ ] FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 495 BROADWAY 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: 2129419500 MAIL ADDRESS: STREET 1: BELSON ENTERPRISES, INC. STREET 2: 495 BROADWAY CITY: NEW YORK STATE: NY ZIP: 10012 SC 13G/A 1 0001.txt SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) AMENDMENT NO. 2* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) HEMISPHERX BIOPHARMA, INC. -------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE ------------------------------ (Title of Class of Securities) 42366C103 -------------- (CUSIP Number) June 8, 2000 ------------------------------------------------------ (Date of Event Which Requires Filing of this Statement Check the appropriate box to designate the rule pursuant to which this schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 42366C103 --------------------------------------------------------------------------- 1. Names of Reporting Persons, S. S. or I. R. S. Identification Nos. of Above Persons Jerome Belson --------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) N/A (b) N/A --------------------------------------------------------------------------- 3. SEC Use Only --------------------------------------------------------------------------- 4. Citizenship or Place of Organization: United States of America --------------------------------------------------------------------------- Number of Shares Owned by Each Reporting Person with 5. Sole Voting Power: 760,205 shares of Common Stock consisting of 474,505 shares of common stock and 285,700 shares of common stock underlying certain warrants. Mr. Belson has given an irrevocable proxy to William A. Carter, President of Hemispherx Biopharma, to vote 50,000 shares of Mr. Belson's common stock. --------------------------------------------------------------------------- 6. Shared Voting Power: N/A --------------------------------------------------------------------------- 7. Sole Dispositive Power: 760,205 shares of Common Stock --------------------------------------------------------------------------- 8. Shared Dispositive Power: N/A --------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 760,205 shares of Common Stock, without par value --------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares: N/A --------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9): 2.6 % --------------------------------------------------------------------------- 2 12. Type of Reporting Person: IN --------------------------------------------------------------------------- Item 1. 1(a). Name of Issuer. Hemispherx Biopharma, Inc. 1(b). Address of Issuer's Principal Executive Offices. One Penn Center 1617 JFK Blvd., Suite 660 Philadelphia, PA 19103 Item 2. 2(a). Name of Person Filing. Jerome Belson 2(b). Address of Principal Business Office. 495 Broadway - 6th Floor New York, New York 10012 2(c). Citizenship. United States of America 2(d). Title of Class of Securities. Common Stock, $.001 par value. 2(e). CUSIP Number. 42366C103 Item 3. N/A Item 4. Ownership. (a) Amount Beneficially Owned: 760,205 (b) Percent of Class: 2.6 % (c) Number of Shares as to which such person has: (i) Sole power to vote or to direct the vote 760,205 (ii) Shared power to vote or to direct the vote 0. (iii) Sole power to dispose or to direct the disposition of 760,205 (iv) Shared power to dispose or to direct the disposition of 0. 3 Item 5. Ownership of Five Percent or Less of a Class. [X] Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. N/A Item 8. Identification and Classification of Members of a Group. N/A Item 9. Notice of Dissolution of Group: N/A Item 10. Certification: (b) The following certification shall be included if the statement is filed pursuant to rule 13d-1(c). By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and were not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction have that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. July 5, 2000 ----------------------------- (Date) /s/ Jerome Belson ----------------------------- (Signature) Jerome Belson ----------------------------- (Name/Title) The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U. S. C. 1001). 4 -----END PRIVACY-ENHANCED MESSAGE-----